BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by frankmanon Dec 09, 2024 3:32pm

27 Views

Post# 36353325

1 million shares traded today with U.S OTC 881k CDN

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr
ATS	226.1	0.05	·	0.06	72.0	0.055	-0.005	-8.3	881.8	42	152
CSE - C	226.1	0.05	·	0.06	72.0	0.055	-0.005	-8.3	399.9	20	54
NEO ATS - U						0.055	-0.005	-8.3	85.0	4	15
Omega - O						0.055	-0.005	-8.3	219.0	11	25
Chi-X - X						0.055	-0.005	-8.3	1.0		1
CX2 - H						0.055	-0.005	-8.3	160.5	7	38
CXD - D						0.06			1.2		5
TriAct - M						0.06			5.2		13
CS2 - S						0.055	-0.005	-8.3	10.0	1	1